Dragon's Blood Modulates Disulfidptosis-Related Genes to Alleviate Ischemic Brain Injury in Mice
- PMID: 40478465
- DOI: 10.1007/s11064-025-04428-5
Dragon's Blood Modulates Disulfidptosis-Related Genes to Alleviate Ischemic Brain Injury in Mice
Abstract
Dragon's Blood (DB), a natural resin extracted from Dracaena cochinchinensis, exhibits anti-inflammatory and neuroprotective properties, but its efficacy and underlying mechanisms in ischemic stroke remain to be fully elucidated. In this study, the neuroprotective effects of DB were evaluated using both transient and permanent middle cerebral artery occlusion (tMCAO and dMCAO) models in mice. DB treatment significantly reduced infarct volume, improved neurological outcomes, and alleviated neuronal apoptosis. Transcriptomic profiling revealed that DB modulated signaling pathways related to neuroinflammation, blood-brain barrier (BBB) integrity, and actin cytoskeleton remodeling. These effects were supported by decreased Evans blue leakage, upregulated expression of tight junction proteins (ZO-1 and Claudin-5), and suppressed pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and iNOS, along with increased levels of Arg-1 and IL-10. Moreover, DB downregulated disulfidptosis-related genes such as Flna, Iqgap1, Tln1, and Myh9. Molecular docking further suggested that Loureirin B, a major active constituent of DB, binds strongly to these targets, indicating a potential mechanistic link. These findings suggest that DB confers multi-target neurovascular protection in ischemic stroke by regulating inflammation, preserving BBB function, and inhibiting disulfidptosis, supporting its potential as a candidate for therapeutic development.
Keywords: Actin cytoskeleton; Disulfidptosis; Dragon's blood; Ischemic stroke; RNA sequencing.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical Approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Animal Ethics Committee of capital medical university (AEEI-2023-229). Competing Interests: The authors declare no competing interests.
References
-
- Pan JJ, Qi L, Wang L (2024) M2 microglial extracellular vesicles attenuated Blood-brain barrier disruption via MiR-23a-5p in cerebral ischemic mice. Aging Dis 15(3):1344–1356. https://doi.org/10.14336/ad.2023.0714 - DOI - PubMed - PMC
-
- Goel D, Shangari S, Mittal M, Bhat A (2024) Endogenous defense mechanism-based neuroprotection in large-vessel acute ischemic stroke: A hope for future. Brain Circ 10(1):51–59. https://doi.org/10.4103/bc.bc_56_23 - DOI - PubMed - PMC
-
- Fan JY, Yi T, Sze-To CM (2014) A systematic review of the botanical, phytochemical and Pharmacological profile of Dracaena Cochinchinensis, a plant source of the ethnomedicine Dragon’s blood. Molecules 19(7):10650–10669. https://doi.org/10.3390/molecules190710650 - DOI - PubMed - PMC
-
- Xin N, Li YJ, Li X (2012) Dragon’s blood May have radioprotective effects in radiation-induced rat brain injury. Radiat Res 178(1):75–85. https://doi.org/10.1667/rr2739.1 - DOI - PubMed
-
- Ran Y, Xu B, Wang R (2016) Dragon’s blood extracts reduce radiation-induced peripheral blood injury and protects human megakaryocyte cells from GM-CSF withdraw-induced apoptosis. Phys Med 32(1):84–93. https://doi.org/10.1016/j.ejmp.2015.09.010 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
